Gene signatures derived from AMLs with promoter–stem cell enhancer activity and stem cell factor expression are associated with clinical outcome. (A) Unsorted cytogenetically normal AML samples (161) were divided into 2 populations by the P-SCE-sig derived from the PCA in Figure 4D (see supplemental Figure 6 and supplemental Experimental Procedures for details) using the k-means clustering algorithm. The panel to the left shows Kaplan-Meier plots for OS and the panel to the right for EFS. Subjects represented by the blue line (G2) show worse OS and OFS than those represented by the gray line (G1). (B) The cytogenetically normal AML samples were divided based on similarity of their transcriptomes to the green group or the yellow and red groups. The panel to the left shows Kaplan-Meier plots for OS and the panel to the right for event free survival. The green line represents subjects whose AML cells show higher concordance with patients with no promoter-enhancer activity (green group) and the red line represents subjects whose AML cells show higher concordance with patients with promoter-enhancer activity (red/yellow). (C) The cytogenetically normal AML samples were divided into 2 populations based on expression levels of the Heptad genes (Heptad-sig) using the k-means clustering algorithm. The panel to the left shows Kaplan-Meier plots for OS and the panel to the right for EFS.